Jurnal Kesehatan Reproduksi
Vol 2, No 2 (2015)

PERBANDINGAN COMPLETE RESPONSE PENDERITA KANKER OVARIUM STADIUM LANJUT YANG MENDAPAT REJIMEN PACLITAXEL-CARBOPLATIN DENGAN REJIMEN CYCLOPHOSPHAMIDE-ADRIAMYCIN-CISPLATIN SEBAGAI KEMOTERAPI LINI PERTAMA

M. Sibuea (Gadjah Mada University)
M. Lutfi (Unknown)
M. Hakimi (Unknown)



Article Info

Publish Date
15 Aug 2016

Abstract

PERBANDINGAN COMPLETE RESPONSE PENDERITAKANKER OVARIUM STADIUM LANJUT YANG MENDAPATREJIMEN PACLITAXEL-CARBOPLATIN DENGAN REJIMENCYCLOPHOSPHAMIDE-ADRIAMYCIN-CISPLATIN SEBAGAIKEMOTERAPI LINI PERTAMAM. Sibuea1, M. Lutfi2, M. Hakimi3ABSTRACTBackground: Introduction of Platinum and Paclitaxel has increased survival rate in advanced epithelialovarian cancer. Several studies have been tried to establish the better combination with those anticancerdrugs.Objectives: Comparing complete response (CR) and progression-free survival (PFS) between Paclitaxel-Carboplatin and CAP as a first line treatment in advanced epithelial ovarian cancer.Method: This research used cohort retrospective study. Fifthy-three subjects with epithelial ovarian cancerFIGO stage III and IV were collected from Dr.Sardjito Hospital’s medical record analysis between January2009 and December 2013, and divided into two groups according to chemotherapy regimens. Completeresponse and progression-free survival were determined after cytoreductive surgery and total 6 coursesof chemotherapy.Result and Discussion: The frequency of complete response was similar, 61,5% in Paclitaxel Carboplatingroup as compared with 63% in CAP group (RR 0,977, 95% CI 0,642-1,487, p=1,000). Kaplan-Meier curvesshowed no difference in progression-free survival between the groups, with median PFS was 15 months(95% CI 13,228-16,772) on Paclitaxel-Carboplatin and 14 months on CAP (95% CI 7,686-20,314) (p logrank=0,741). Patients undergo optimal cytoreductive surgery attained more complete response (OR 8,274,95% CI 1,775-38,559, p=0,007) and had a longer PFS than the suboptimal group (17 vs 13 months, p logrank=0,046).Conclusion: Paclitaxel-Carboplatin was not superior compared with CAP regimen as first line chemotherapyin advanced epithelial ovarian cancer. Further evaluation of survival, toxicity profile, and quality of lifewere needed to determine superiority of Paclitaxel-Carboplatin compared with CAP. Optimal cytoreductivesurgery was an independent predictor for a better prognosis.Keywords: advanced ovarian cancer, chemotherapy, Paclitaxel-Carboplatin, CAPABSTRAKLatar belakang: Survival rate penderita kanker ovarium epitelial stadium lanjut meningkat sejakdiperkenalkannya Platinum dan Paclitaxel. Beberapa penelitian telah berusaha untuk menentukankombinasi yang lebih baik dari obat-obatan tersebut.Tujuan: Membandingkan complete response (CR) dan progression-free survival (PFS) antara Paclitaxel-Carboplatin dengan CAP sebagai terapi lini pertama pada kanker ovarium epitelial stadium lanjut.Metode: Penelitian ini menggunakan studi cohort retrospective. Lima puluh tiga subyek dengan kankerovarium epitelial stadium III-IV (FIGO) didapatkan dari analisis rekam medis RSUP Dr. Sardjito mulai Januari2009 hingga Desember 2013, yang terbagi menjadi dua kelompok berdasarkan jenis kemoterapi yang diterima. Complete response dan PFS ditentukan setelah pasien menjalani operasi sitoreduksi dan total 6 siklus kemoterapi.Hasil dan Pembahasan: Frekuensi CR kelompok Paclitaxel Carboplatin (61,4%) serupa dengan kelompokCAP (63%) (RR 0,977, 95% CI 0,642-1,487, p=1,000). Kurva Kaplan-Meier tidak menunjukkan perbedaanPFS di antara kedua kelompok, dengan median PFS Paclitaxel-Carboplatin 15 bulan (95% CI 13,228-16,772)dan CAP 14 bulan (95% CI 7,686-20,314) (p log-rank=0,741). Pasien dengan operasi sitoreduksi optimalmencapai CR lebih banyak (OR 8,274, 95% CI 1,775-38,559, p=0,007) dan median PFS lebih panjang dibandingkan dengan kelompok suboptimal (17 vs 13 bulan, p log-rank=0,046).Kesimpulan: Paclitaxel-Carboplatin tidak lebih superior dibandingkan dengan CAP sebagai kemoterapi linipertama pada kanker ovarium epitelial stadium lanjut. Namun, masih diperlukan pengukuran survival, profiltoksisitas, dan kualitas hidup guna menentukan keunggulan rejimen Paclitaxel-Carboplatin dibandingkan dengan CAP. Operasi sitoreduksi yang optimal merupakan prediktor independen dari prognosis yang lebih baik.Kata kunci: kanker ovarium stadium lanjut, kemoterapi, Paclitaxel-Carboplatin, CAP1,2,3 Bagian Obstetri dan Ginekologi FK UGM/RSUP Dr. Sardjito Yogyakarta

Copyrights © 2015






Journal Info

Abbrev

jkr

Publisher

Subject

Health Professions Medicine & Pharmacology Nursing Public Health

Description

urnal Kesehatan Reproduksi is a scientific journal published by Association of Women and Children Reproductive Health Enthusiasts and Experts/Ikatan Pemerhati Anak dan Kesehatan Reproduksi/IPAKESPRO) who works closely with the Department of Obstetrics and Gynaecology, Faculty of Medicine, Public ...